The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
But the Day One deal is still 29% below where the shares stood at the start of this year.
The company ditches lorigerlimab in prostate cancer.
The response rate jumps to 30% with higher doses of IMA402.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
After more discontinuations, a new deal brings in fresh blood.
The CD70-targeting CTX131 heads for the scrapheap.
